MediciNova, Inc. (MNOV)
Company Description
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States.
It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction.
The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers.
It has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.
| Country | United States |
| Founded | 2000 |
| IPO Date | Feb 8, 2005 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Dr. Yuichi Iwaki M.D., Ph.D. |
Contact Details
Address: 4275 Executive Square, Suite 300 La Jolla, California 92037 United States | |
| Phone | 858-373-1500 |
| Website | medicinova.com |
Stock Details
| Ticker Symbol | MNOV |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001226616 |
| CUSIP Number | 58468P206 |
| ISIN Number | US58468P2065 |
| Employer ID | 33-0927979 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Yuichi Iwaki M.D., Ph.D. | Co-Founder, President, Chief Executive Officer and Executive Director |
| Dr. Kazuko Matsuda M.D., M.P.H., MPH, Ph.D. | Chief Medical Officer and Director |
| Jason J. Kruger CPA | Chief Financial Officer and Principal Financial Officer |
| Dr. David H. Crean M.B.A., Ph.D. | Chief Business Officer |
| John O'Neil CPA | Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 9, 2023 | 10-Q | Quarterly Report |
| Aug 9, 2023 | 10-Q | Quarterly Report |
| Aug 7, 2023 | 8-K | Current Report |
| Jun 22, 2023 | 8-K | Current Report |
| Jun 14, 2023 | 8-K | Current Report |
| May 11, 2023 | 10-Q | Quarterly Report |
| Apr 26, 2023 | 8-K | Current Report |
| Apr 26, 2023 | ARS | Filing |
| Apr 26, 2023 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 26, 2023 | DEF 14A | Other definitive proxy statements |